Major Depressive Disorder Clinical Trial
Official title:
Feasibility and Acceptability Study of "Mamá, te Entiendo": an App-based Intervention for Reducing Depressive Symptoms in Postpartum Women
Title: "Feasibility and acceptability study of "Mamá, te entiendo": an app-based intervention for reducing depressive symptoms in postpartum women" Funding: This work was funded by the Chilean National Agency of Research and Development (ANID Doctorado Nacional 2019 - 21190745). General objective: To assess the feasibility and acceptability of a guided 8-week cognitive-behavioral app-based intervention for Chilean postpartum women with depressive symptoms. Design: A small-scale parallel 2-arms trial will be conducted. Postpartum women with minor or major depression will be randomized to the app-based intervention or waitlist. The primary outcomes are feasibility and acceptability variables, mainly; recruitment and eligibility rates, intervention and study adherence, and participants' intervention satisfaction, use, and engagement. Semi-structured interviews with a sub-sample will provide more information about the participants' experience with the intervention. Women's depression diagnostic status will be assessed at pre-treatment, post-treatment, and 1-month follow-up. Other secondary outcomes will include participants' perceived social support, mother-infant bonding, and maternal satisfaction and self-efficacy.
Status | Not yet recruiting |
Enrollment | 66 |
Est. completion date | November 1, 2023 |
Est. primary completion date | November 1, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Women will be included if they: - have a < 6-month-old baby, - have a PHQ-9 (Kroenke et al., 2001; Diez-Quevedo et al., 2001) score = 5 points, - have minor or major depression according to the Mini-International Neuropsychiatric Interview (MINI: Sheehan et al., 1999; Ferrando et al., 2000), - are at least 18 years old, - are Chilean residents, - are fluent in written and spoken Spanish, - self-report ownership of a smartphone, and - self-report regular access to the internet. Minor depression will be defined as the presence of two to four concurrent symptoms of depressive disorder (one of which is depressed mood or anhedonia) present most or all the time for at least two weeks, with symptoms causing dysfunction and negative impact on the individual's life (American Psychiatric Association, 2013). Major depression will be defined as the presence of five or more concurrent symptoms of depressive disorder (one of which is depressed mood or anhedonia) present most or all the time for at least two weeks, with symptoms causing dysfunction and a negative impact on the individual's life (American Psychiatric Association, 2013). Exclusion Criteria: Participants exclusion criteria will be the following: illiteracy, risk of suicide, alcohol or substance abuse, bipolar disorder, and psychotic disorder. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Pontificia Universidad Catolica de Chile | Agencia Nacional de Investigación y Desarrollo, Instituto Milenio para Investigación en Depresión y Personalidad |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intervention's acceptability by credibility/expectancy | The CEQ is used to assess treatment credibility and expectancy of benefit. The CEQ is a 6-item self-report questionnaire that measures treatment credibility, defined as "how believable, convincing, and logical the treatment is" and expectancy, defined as "improvements the client believes will be achieved". Scores range from 0 to 100 with higher scores indicating higher acceptability of the intervention. Therefore, higher scores mean better outcomes. | T0: baseline | |
Primary | Satisfaction with the intervention | The Client Satisfaction Questionnaire is used to assess satisfaction with the intervention. It is an 8-item self-report questionnaire that assesses the general level of satisfaction with a service received. The total score ranges from 8 to 32. Higher score indicates greater satisfaction. | T1 (post test: 8 weeks) | |
Primary | Participants' adherence to the intervention | Percentage of participants who completed all main modules. | T1 (post test: 8 weeks) | |
Primary | Participants' usability of the intervention | Average, range, and standard deviation of the number of main modules completed. | T1 (post test: 8 weeks) | |
Primary | Participants' adherence to the homework exercises | Average, range, and standard deviation of homework exercises sent to the e-coach. | T1 (post test: 8 weeks) | |
Primary | Engagement with the intervention | Engagement with the intervention is assess by the TWEETS. The TWEETS is a 9-item self-report measure that assesses engagement with an eHealth technology. Of the nine items, three are aimed at assessing behavioral engagement, three at cognitive engagement, and three at affective engagement. Each item is measured on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree". The total score ranges from 0 to 36. Higher scores indicate greater engagement. | T1 (post test: 8 weeks) | |
Primary | Intervention's acceptability by participant's experience | A sub-sample of participants from the intervention group will be invited to participate in semi-structured interviews. The interviews will explore positive and negative impressions and general experiences with the intervention and study procedures. The interviews will be analysed through thematic analysis. | After T2 (follow-up: 12 weeks) | |
Primary | Resources needed to complete the intervention | Length of time required for e-coaches to deliver the intervention. | Through the study, in average 8 months | |
Secondary | Change in depression diagnosis | The Spanish version of the Mini-international neuropsychiatric interview will be used to assess eligibility (diagnosis of minor or major depression) and as an outcome measure. At T1 and T2, only the "Major Depressive Episode" section will be used.
Participants fulfilling five out of nine depressive symptoms for at least 2 weeks (with at least one symptom as depressed mood or loss of interest) will be diagnosed as having major depressive disorder. Those fulfilling two to four of the nine symptoms (with at least one symptom being depressed mood or loss of interest) will be diagnosed with minor depressive disorder. Those with less than two symptoms will be diagnosed as in remission. |
T0 (Baseline), T1 (post test: 8-weeks) and T2 (follow-up: 12-weeks) | |
Secondary | Change in depressive symptoms | The Patient Health Questionnaire -9 is used to meassure depressive symptoms. The PHQ-9 is a 9-item self-report measure of depressive symptoms experienced over the past two weeks. It is based on the Diagnostic Statistical Manual, fourth edition diagnostic criteria for major depressive disorder. Participants rate the frequency of symptoms (e.g., 'Feeling down, depressed, or hopeless') on a 4-point scale ranging from "not at all" to "nearly every day". Total scores range from 0 (no symptoms) to 27 (severe). Scores > 9 are indicative of a clinically significant level of depressive symptoms. | T0 (Baseline), T1 (post test: 8-weeks) and T2 (follow-up: 12-weeks) | |
Secondary | Change in postpartum depressive symptoms | The Edinburgh Postpartum Depression Scale is used to assess postpartum depressive symptoms. It consists of ten multiple-choice questions on a 4-point scale ranging from 0 to 3 according to the severity of the symptoms. The total score goes from 0 (no symptoms) to 30 (severe symptoms). It has been validated in various countries and cultures, including Chile. Higher scores indicate more significant depressive symptoms, and three categories of depressive symptomatology are identified: no risk, probable risk, and probable depression. | T0 (Baseline), T1 (post test: 8-weeks) and T2 (follow-up: 12-weeks) | |
Secondary | Change in perceived social support | The Multidimensional Scale of Perceived Social Support is used to measure perceived social support. It is a 12-item measure of perceived adequacy of social support from three sources: family, friends, and significant other. It was translated and validated in Chile. In the Chilean version, the questions are rated on a 4-point scale ranging from "rarely" to "always". Higher score indicates greater perceived social support. | T0 (Baseline) and T2 (follow-up: 12-weeks) | |
Secondary | Change in mother-infant bonding | The Postpartum Bonding Questionnaire is used to measure mother-infant bonding. It is a 25-item self-report measure that assesses mother-infant bonding through the mother's feelings and attitudes toward her infant. The questions are rated on a 6-point Likert scale ranging from "not at all" to "always". A validated Spanish version of the PBQ will be used in this study. The total score ranges from 0 to 75. Higher score indicates greater mother-infant bonding. | T0 (Baseline) and T2 (follow-up: 12-weeks) | |
Secondary | Change in satisfaction and self-efficacy regarding motherhood | The Escala de Evaluación Parental [Parental Assessment Scale] is used to measure satisfaction and self-efficacy regarding motherhood. It is a 10-item self-report measure that assesses satisfaction and self-efficacy regarding motherhood in women with children between 0 and 2 years of age. Each item is measured on a 10-point Likert-type scale, ranging from "totally Disagree" to "totally agree"). The scale was developed and validated in Chile. The total score ranges from 0 to 10. Higher score indicates greater satisfaction and self-efficacy regarding motherhood. | T0 (Baseline) and T2 (follow-up: 12-weeks) | |
Secondary | Mental Healthcare Services Use from T0 to T1 | Participants will be asked if they have use mental health services since T0 (baseline), i.e., whether the participant is currently undergoing any treatment (pharmacotherapy/psychotherapy/both/none). | T1 (post test: 8-weeks) | |
Secondary | Mental Healthcare Services Use from T1 to T2 | Participants will be asked if they have use mental health services since T1 (post test), i.e., whether the participant is currently undergoing any treatment (pharmacotherapy/psychotherapy/both/none). | T2 (follow-up: 12-weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |